Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 9

  • 849 clinical trials
  • 267 recruiting
  • 359 conditions
  • 25 countries

Conditions in this area

359 conditions with trials, the busiest first

Dermatitis atopic89Malignant melanoma79Systemic lupus erythematosus63Psoriasis54Hidradenitis47Psoriatic arthropathy46Systemic scleroderma40Metastatic malignant melanoma32Vitiligo24Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis16Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Basal cell carcinoma12Diabetic foot12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+335

Clinical trials in Skin and subcutaneous tissue disorders

849 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

849 clinical trials

Systemic scleroderma

Recruiting

Study of adipose-derived mesenchymal stem cell injections to treat mouth fibrosis in patients with systemic scleroderma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Albumin
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Glomerulonephritis membranous+4

Recruiting

Study of Atacicept Treatment for Patients with Multiple Autoimmune Glomerular Diseases

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Atacicept
  • Sponsor:Vera Therapeutics Inc.

Bullous impetigo+3

Recruiting

Comparing two forms of mupirocin (gel and ointment) for treating impetigo in children: a study of different dosing schedules

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Sponsor:Laboratorios Ojer Pharma S.L.

Systemic scleroderma+2

Recruiting

Study of Blinatumomab Treatment in Patients with Systemic Lupus Erythematosus, Systemic Sclerosis, or Granulomatosis with Polyangiitis: Safety and Effectiveness Evaluation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Universitaet Leipzig

Malignant melanoma

Recruiting

Study to Evaluate IOpener-Melanoma Test for Predicting Response to Immunotherapy in Stage III or IV Skin Melanoma Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Leiden University Medical Center

Basal cell carcinoma

Recruiting

Study of Cemiplimab Combined with Imiquimod and Laser Therapy Before Surgery for High-Risk Skin Basal Cell Carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Instituto Oncologico Dr. Rosell S.L.

Malignant melanoma

Recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with Metastatic Melanoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Dermatitis atopic

Recruiting

Effectiveness and Safety of Abrocitinib in Children 6 to Under 12 Years with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Abrocitinib
  • Sponsor:Pfizer Inc.

Malignant melanoma

Recruiting

Vusolimogene Oderparepvec with Nivolumab for Advanced Melanoma Patients Whose Cancer Progressed After Previous Immunotherapy Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dacarbazine Citrate
  • Sponsor:Replimune Group Inc.

Psoriatic arthropathy

Recruiting

Study on Lutikizumab and Risankizumab for Adults with Active Psoriatic Arthritis

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Psoriatic arthropathy

Recruiting

Study on the Effectiveness of Ixekizumab for Patients with Refractory Psoriatic Arthritis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ixekizumab
  • Sponsor:University Hospital Of Ferrara

Diabetic foot+1

Recruiting

Study on the Effect of Semaglutide on Healing Foot Ulcers in Patients with Type 2 Diabetes

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Region Hovedstaden

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.